

## Invitation to presentation of Xbrane Biopharma's interim report January – September 2020 on November 13, 2020.

**Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on November 13, 2020, at 10.00 a.m. CET. Xbrane will publish the company's interim report January – September 2020, on Friday November 13, 2020, at 8.00 a.m. CET.**

Martin Åmark, CEO, and Margareta Hagman, Interim CFO, will present Xbrane and the interim report January – September 2020, followed by a Q&A session. The presentation will be in English. To attend, please dial-in at one of the numbers below or click on the link below to follow the presentation.

Standard international: +44 (0) 2071 928338

UK (Local): +44 (0) 8444819752

UK (Tollfree): 08002796619

Sweden (Local): +46 (0) 856618467

Sweden (TollFree): 0200125160

US (Local): +1 6467413167

US (TollFree): +1 8778709135

Confirmation Code: 1225339

Web link:

<https://edge.media-server.com/mmc/p/jcuq48x6>

### Contacts

Martin Åmark, CEO/ IR

M: +46 (0) 763-093 777

E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

### About Us

*Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit [www.xbrane.com](http://www.xbrane.com).*

Press Release  
12 November 2020 10:30:00 CET

---



## Attachments

---

[Invitation to presentation of Xbrane Biopharma's interim report January – September 2020 on November 13, 2020.](#)